

# ACT-FASTER, a Prospective Cohort Study Exploring Treatment with Anastrozole and Exemestane in Postmenopausal Patients with Advanced Breast Cancer under Real-Life Conditions in Germany

Breast Care

14, 401-408

DOI: [10.1159/000493882](https://doi.org/10.1159/000493882)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Fulvestrant in hormone-positive advanced breast cancer: Real-world outcome. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 275.	0.1	5
2	Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. <i>Cancers</i> , 2021, 13, 5643.	1.7	16
3	Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence. <i>Advances in Therapy</i> , 2022, 39, 862.	1.3	5
4	Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER- $\beta$ Axis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3